If they do, they could potentially
make nanomedicines already in clinical trials even more effective.
Not exact matches
In his first few years as a principal investigator (PI), working with stem cells and emerging nanotechnologies to develop
nanomedicines, Ferreira was able to
make do by licensing some of his technologies and securing industry funding and Portuguese government grants.
«Despite huge efforts in the field of
nanomedicine, fewer nanoparticle technologies than expected have
made it to clinical trials.
The tough challenges we faced were to
make this nanocapsule stable and biocompatible, while at the same time controlling the release of the drug at the desired rate over months,» added Prof Venkatraman, the founding director of the NTU - Northwestern Institute for
Nanomedicine.
In this study, targeted
nanomedicines made from polymeric building blocks that are utilized in numerous FDA approved products to date, were nanoengineered to carry an anti-inflammatory drug payload in the form of a biomimetic peptide.
As such, it is the beginning of an experiment in itself to rethink
nanomedicine in the
making.